MYGN:NGS-Myriad Genetics Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 27.97

Change

+0.16 (+0.58)%

Market Cap

USD 1.17B

Volume

0.83M

Analyst Target

USD 15.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 38.79B
ICLR ICON PLC

N/A

USD 25.88B
ILMN Illumina Inc

N/A

USD 20.48B
NTRA Natera Inc

N/A

USD 14.01B
EXAS EXACT Sciences Corporation

N/A

USD 11.40B
MEDP Medpace Holdings Inc

N/A

USD 10.76B
RDNT RadNet Inc

N/A

USD 4.64B
SHC Sotera Health Co

N/A

USD 4.37B
NEOG Neogen Corporation

N/A

USD 3.49B
GH Guardant Health Inc

N/A

USD 3.00B

ETFs Containing MYGN

MXF:CA 4.70 % 0.74 %

N/A

N/A
GNOM Global X Genomics & Biote.. 4.27 % 0.00 %

N/A

USD 0.09B
GNOG:LSE Global X Genomics & Biote.. 4.19 % 0.00 %

N/A

USD 6.11M
GN0M:XETRA Global X Genomics & Biote.. 4.08 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.08 % 0.00 %

N/A

USD 5.87M
HEP:CA 0.00 % 0.83 %

N/A

N/A
EMXC iShares MSCI Emerging Mar.. 0.00 % 0.41 %

N/A

USD 15.88B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 46.13% 88% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.13% 88% B+ 90% A-
Trailing 12 Months  
Capital Gain 31.38% 85% B 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.38% 85% B 83% B
Trailing 5 Years  
Capital Gain -40.59% 50% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.59% 50% F 27% F
Average Annual (5 Year Horizon)  
Capital Gain 12.52% 65% D 71% C-
Dividend Return 12.52% 65% D 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 62.67% 39% F 25% F
Risk Adjusted Return 19.98% 76% C+ 55% F
Market Capitalization 1.17B 74% C 81% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.00 48% 30%
Price/Book Ratio 2.24 50% 44%
Price / Cash Flow Ratio -21.19 86% 89%
Price/Free Cash Flow Ratio -8.96 81% 83%
Management Effectiveness  
Return on Equity -29.41% 63% 40%
Return on Invested Capital -16.94% 65% 35%
Return on Assets -6.60% 67% 38%
Debt to Equity Ratio 4.92% 82% 78%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector